Table 2: The genotype frequencies of the CYP17, CYP1B1, CYP1A1, and COMT gene variants in breast cancer patients and controls, and after menopause.

GenotypeBreast cancer patients ( )Controls ( )OR (95% CI)P value
NumberFrequencyNumberFrequency

CYP17
Premenopause
 TT160.25220.351.0 (reference).81
 TC+CC140.23170.271.1 (0.4-2.9)
Postmenopause
 TT110.18160.261.0 (reference).01
 TC+CC210.3470.124.3 (1.3–13.7)
CYP1B1
Premenopause
 Val/Val60.1150.241.0 (reference).11
 Val/Leu+Leu/Leu240.39240.392.5 (0.8–7.5)
Postmenopause
 Val/Val110.1860.11.0 (reference).56
 Val/Leu+Leu/Leu210.33170.270.6 (0.2–2.1)
CYP1A1
Premenopause
 TT160.25360.581.0 (reference).0004
 TC+CC140.2330.0510.5 (2.6–41.7)
Postmenopause
 TT240.39170.271.0 (reference)1.0
 TC+CC80.1360.10.9 (0.2–3.2)
COMT
Premenopause
 Val/Val100.16240.381.0 (reference).02
 Val/Met+Met/Met200.32150.243.2 (1.1–8.6)
Postmenopause
 Val/Val110.18120.21.0 (reference).2
 Val/Met+Met/Met210.34110.182.0 (0.6–6.2)